Stock Analiz

Myriad Genetics Inc. MYGN

Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 1995 · data as of November 13, 2026

$5.66Market cap $543M
Open the interactive analysis →

Myriad Genetics Inc. (MYGN) is a healthcare company listed in the US with a market value of about $543M. In the twelve months to September 30, 2026 it had revenue of $804M and net income of -$129M, a net margin of -16.1%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 8% a year, a 5-year average ROIC of -24%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 89% below the current price.

About Myriad Genetics

Myriad Genetics is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 1995. Revenue went from $723M in 2015 to $824M in 2025, growth of about 1.3% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 15% over three years (dilution for shareholders). It spends 13% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.7
P/B2.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-6.9%
Shareholder yield0.0%
Intrinsic value vs. price−89%

Growth and quality

Revenue growth (1 yr)-1.6%
Revenue growth (5 yrs, per year)8.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-23.0%
ROIC (5-yr avg.)-24.1%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$804M$824M$838M$753M$678M$691M$557M$851M$744M$771M$754M
Net income-$129M-$366M-$127M-$263M-$112M-$27M-$224M$5M$133M$17M$117M
Free cash flow-$38M—-$19M-$121M-$152M$600000—$75M$108M$100M$161M
EPS (diluted)$-1.35$-3.95$-1.41$-3.18$-1.39$-0.35$-2.99$0.06$1.85$0.25$1.60
Net margin-16.1%-44.4%-15.2%-35.0%-16.5%-3.9%-40.1%0.5%17.9%2.3%15.6%
ROIC—-62.1%-11.6%-21.7%-10.9%-14.2%-19.5%0.4%9.9%4.0%15.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $5.90, 4% above the current price; targets range from $3.80 to $8.00; the consensus rating is “Hold”; expected EPS is $-0.69 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Myriad Genetics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 89% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Myriad Genetics pay a dividend?

Not currently.

Is Myriad Genetics a good stock to buy?

We do not give buy or sell advice. Myriad Genetics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.